About TrialNet Studies

Ongoing studies:

• The Natural History Study of the Development of Type 1 Diabetes (Currently Recruiting)
  will study people at increased risk for type 1 diabetes to learn more about how type 1 diabetes occurs.
• The Oral Insulin for Prevention of Type 1 Diabetes Study (Currently Recruiting)
  TrialNet has launched a clinical study of oral insulin to prevent or delay type 1 diabetes in at-risk people. Our goal is to prevent type 1 diabetes or to delay it as long as possible.
• CTLA-4 Ig (Abatacept) in Recent Onset Diabetes(Currently Recruiting)
  is trying to see if it is possible to use the drug abatacept to stop or slow down the immune system's attack in newly diagnosed type 1 diabetes patients so that the remaining beta cells can survive and keep making some of the insulin your body needs.
• T1DGC (Currently Recruiting)
  Type 1 Diabetes Genetics Consortium (www.t1dgc.org) is a group of diabetes researchers from around the world who have come together to collect blood samples and information from families with type 1 diabetes.
• The Nutritional Intervention to Prevent Type 1 Diabetes Study (This study is no longer recruiting patients)
  The Nutritional Intervention to Prevent Type 1 Diabetes study will help us learn more about a dietary substance, docosahexaenoic acid (DHA) when given to pregnant mothers in their third trimester and infants less than 5 months of age. This research is being done as a pilot study, which is a "test run" to find out if it is possible to do a larger study.
• The Rituximab Study (Anti-CD20) (This study is no longer recruiting patients.)
  This study is trying to see if it is possible to stop or slow down the immune system's attack in newly diagnosed type 1 diabetes patients so that the remaining beta cells can survive and keep making some of the insulin your body needs.
• The MMF/DZB Study (This study is no longer recruiting patients.)
  will see whether a combination of two medicines can stop the immune system from destroying beta cells in new onset type 1 diabetes patients (within 3 months of diagnosis).